← Back to Search

Alkylating agents

Golcadomide + R-CHOP for B-Cell Lymphoma (GOLSEEK-1 Trial)

Phase 3
Recruiting
Research Sponsored by Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial aims to see if adding golcadomide to R-CHOP chemotherapy is more effective and safe than R-CHOP chemotherapy alone in patients with a specific type of lymphoma.

Who is the study for?
This trial is for adults with a new diagnosis of high-risk large B-cell lymphoma, including several specific subtypes. Participants must have an IPI score indicating moderate to high risk and measurable disease by certain medical imaging criteria. They cannot join if they have other types of lymphoma, CNS involvement by the lymphoma, or any condition that could interfere with their participation.
What is being tested?
The study is testing the effectiveness and safety of Golcadomide combined with R-CHOP chemotherapy versus a placebo combined with R-CHOP in treating patients who haven't been treated before for high-risk large B-cell lymphoma.
What are the potential side effects?
Potential side effects include those common to chemotherapy such as nausea, hair loss, fatigue, increased infection risk; plus any additional risks associated with Golcadomide which will be monitored throughout the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Golcadomide + R-CHOP (Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone)Experimental Treatment6 Interventions
Group II: Placebo + R-CHOPPlacebo Group6 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Prednisone
2014
Completed Phase 4
~2500
Cyclophosphamide
2010
Completed Phase 4
~2320
Doxorubicin
2012
Completed Phase 3
~8030
Rituximab
1999
Completed Phase 4
~2200
Vincristine
2003
Completed Phase 4
~2970

Find a Location

Who is running the clinical trial?

CelgeneLead Sponsor
645 Previous Clinical Trials
129,699 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,559 Previous Clinical Trials
3,382,866 Total Patients Enrolled
~567 spots leftby Aug 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top